Neuronetics, Inc. is a medical technology company that focuses on developing products to improve the lives of patients with neurohealth disorders the U.S. Food and Drug Administration (FDA) cleared NeuroStar TMS (transcranial magnetic stimulation) for use as a first-line add-on treatment for adolescents aged 15-21 with major depressive disorder (MDD).

This approval positions NeuroStar as the first TMS therapy available for adolescents facing depression, marking a significant advancement in treatment options for this age group.

NeuroStar is proud to share the stories of patients and their families who have experienced the benefits of NeuroStar TMS therapy:

Chrissy, a 15-year-old patient, expressed relief at finding NeuroStar as a treatment option for her deep depression, stating that it made her feel like herself again after years of struggle.

Patricia, a parent of a NeuroStar patient, described the frustration of seeing limited treatment options for her child's depression before discovering NeuroStar TMS, which ultimately proved to be the best decision for her child's well-being.

Shelly, a 25-year-old patient, shared how NeuroStar TMS transformed her life, improving her mood, concentration, and social interactions, leading to a better overall quality of life.

With the FDA clearance, NeuroStar becomes the first and only TMS therapy approved as a primary adjunct treatment for adolescents with depression. This milestone underscores NeuroStar's commitment to providing innovative solutions for mental health care.

NeuroStar encourages healthcare providers, caregivers, and individuals affected by adolescent depression to explore its clinically-proven TMS therapy solution during Mental Health Awareness Month and beyond.

 

 

Source: globenewswire.com

Report Abuse